For your de novo adult renal transplant patients at low to moderate immunologic risk

proven efficiacy
early targeted csa reduction
clinical safety experience
  • one
  • two
  • three
isi

References: 1. Tedesco Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant. 2010;10:1401-1413. 2. ZORTRESS [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2013.